Re­gen­eron picks a new de­liv­ery tech in ef­fort to up­grade flag­ship block­buster Eylea

Last year, Re­gen­eron re­port­ed $2.7 bil­lion in Eylea sales, pro­ject­ing $3.2 bil­lion for this year. And now, 5 years af­ter the block­buster ap­proval that set the com­pa­ny up for one of the most re­mark­able R&D runs in biotech, the com­pa­ny is go­ing to work with a new de­liv­ery tech­nol­o­gy to see if they can make a bet­ter drug, with a fresh patent run­way.

This morn­ing, Re­gen­eron $REGN and Oc­u­lar Ther­a­peu­tix $OCUL spelled out a $315 mil­lion deal to use Oc­u­lar’s “hy­dro­gel” on Eylea, ex­plor­ing its po­ten­tial to more durably get the drug in­to the back of the eye, re­duc­ing the num­ber of in­jec­tions pa­tients face when treat­ed for wet, age re­lat­ed mac­u­lar de­gen­er­a­tion and oth­er reti­nal dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.